Source: Annual Congress 2010 - Pharmacological treatment in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola, A. Segreti, G. Bettoncelli, I. Paolini, C. Cricelli, C. Saltini (Rome, Florence, Italy). Changes in drug prescription for asthma (A) and COPD (C) by GPs in Italy. Eur Respir J 2010; 36: Suppl. 54, 855

Member's Comments

No comment yet.

Related content which might interest you: COPD (C) and asthma (A) comorbidities in Italian primary care Source: Annual Congress 2010 - Comorbidity in obstructive airway disease Year: 2010 Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples Source: Eur Respir J 2005; 26: Suppl. 49, 595s Year: 2005 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Study of 793 COPD patients treated by general practitioners (GPs), intensivists (IPs) and pulmonologists (Ps) across India Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 The level of asthma control in patients with asthma in primary care in Sweden. Results from the AIM-study (asthma in middle Sweden) Source: Eur Respir J 2002; 20: Suppl. 38, 395s Year: 2002 Prescription rates for various classes of COPD & asthma medication in Turkey Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Clinical implications of diagnosing underlying chronic bronchitis (CB) in at-risk patients (pts) with acute bronchitis (AB) visiting general practitioners (GPs) Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 Long term oxygen therapy (LTOT) prescription in chronic obstructive pulmonary disease (COPD) patients in Wigan (northwest England) Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Asthma (A) and COPD (C) in an Italian adult population: Relation to sex and smoking habits Source: Annual Congress 2010 - Epidemiological data for smoking control Year: 2010 Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012 COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015 Changes in prescriped inhaled COPD medication during a 3 year period in Denmark. A registry study Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013 Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts) Source: Annual Congress 2013 –COPD treatment Year: 2013